Journal articles: 'Ca 19'

1

Gaillard, O. "CA 19-9." Immuno-analyse & Biologie Spécialisée 16, no. 4 (July 2001): 244–45. http://dx.doi.org/10.1016/s0923-2532(01)80017-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Troalen, Frédéric. "CA 19-9." EMC - Biologie Médicale 1, no. 1 (January 2006): 1–4. http://dx.doi.org/10.1016/s2211-9698(06)76034-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fiala, Ludek, Petr Bob, and Jiri Raboch. "Oncological markers CA-125, CA 19-9 and endometriosis." Medicine 97, no. 51 (December 2018): e13759. http://dx.doi.org/10.1097/md.0000000000013759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Graulet, AM. "Informations réactifs : CA 19-9." Immuno-analyse & Biologie Spécialisée 16, no. 1 (January 2001): 59–64. http://dx.doi.org/10.1016/s0923-2532(01)80011-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Passek, K., M. H. Bendels, D. Ohlendorf, E. Wanke, G. M. Oremek, and D. A. Groneberg. "Der Tumormarker CA 19-9." Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie 67, no. 6 (August 30, 2017): 327–29. http://dx.doi.org/10.1007/s40664-017-0211-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wirquin, V. "Informations réactifs: Marqueurs tumoraux: CA 19-9, CA 125, CA 15-3, CA 50, CA 72-4." Immuno-analyse & Biologie Spécialisée 11, no. 3 (January 1996): 208–11. http://dx.doi.org/10.1016/0923-2532(96)83018-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hoffmann, L., S. Müller-Hagen, G. Franz, R. Klapdor, and M. Dietel. "Die Tumormarker CA 125, CA 19-9, CA 15-3 und CEA beim Ovarialkarzinom." Archives of Gynecology and Obstetrics 242, no. 1-4 (March 1987): 371–72. http://dx.doi.org/10.1007/bf01783165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tekin, Oğuz. "Hypothyroidism-Related CA 19-9 Elevation." Mayo Clinic Proceedings 77, no. 4 (April 2002): 398. http://dx.doi.org/10.4065/77.4.398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ritts, Roy E., and Henry A. Pitt. "CA 19-9 in Pancreatic Cancer." Surgical Oncology Clinics of North America 7, no. 1 (January 1998): 93–101. http://dx.doi.org/10.1016/s1055-3207(18)30286-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

ATIQUZZAMAN, B. "High CA 19?9 in choledocholithiasis." American Journal of Gastroenterology 98, no. 9 (September 2003): S180. http://dx.doi.org/10.1016/s0002-9270(03)01306-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Atiquzzaman, Basher M., Tahsina Y. Atiquzzaman, and Muhammad Abdullah. "HIGH CA 19–9 IN CHOLEDOCHOLITHIASIS." American Journal of Gastroenterology 98 (September 2003): S180. http://dx.doi.org/10.1111/j.1572-0241.2003.08273.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Safi, Farouk, Hans G. Beger, Reinhard Bittner, Markus Büchler, and Wolfgang Krautzberger. "CA 19-9 and pancreatic adenocarcinoma." Cancer 57, no. 4 (February 15, 1986): 779–83. http://dx.doi.org/10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Meredith, K., J. Huston, and R. Shridhar. "Prognostic significance of CA 19-9." HPB 23 (2021): S322. http://dx.doi.org/10.1016/j.hpb.2020.11.819.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Dienst, C., F. G. Hanisch, and G. Uhlenbruck. "Comparison of the tumor markers CA 19–9, CA 12–5, CA 15–3 and CA 50." Journal of Cancer Research and Clinical Oncology 111, S1 (February 1986): S89. http://dx.doi.org/10.1007/bf02580125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Pectasides, D., A. Mylonakis, M. Kostopoulou, M. Papadopoulou, D. Triantafillis, J. Varthalitis, M. Dimitriades, and A. Athanassiou. "CEA, CA 19-9, and CA-50 in Monitoring Gastric Carcinoma." American Journal of Clinical Oncology 20, no. 4 (August 1997): 348–53. http://dx.doi.org/10.1097/00000421-199708000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Martin, Philip. "COVID-19 and California farm labor." California Agriculture 74, no. 2 (June 2020): 67–68. http://dx.doi.org/10.3733/ca.2020a0017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Cirkel, U., H. Ochs, B. Latussek, and H. Schneider. "Aussagekraft der Tumormarker CA 125, CA 19-9, CA 15-3 und CEA bei Endometriose." Geburtshilfe und Frauenheilkunde 51, no. 08 (August 1991): 626–31. http://dx.doi.org/10.1055/s-2007-1026212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Haglund, C., P. J. Roberts, H. Jalanko &, and P. Kuusela. "Tumour Markers CA 19-9 and CA 50 in Digestive Tract Malignancies." Scandinavian Journal of Gastroenterology 27, no. 3 (January 1992): 169–74. http://dx.doi.org/10.3109/00365529208999944.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Vignali, M., G. Scagnelli, E. Ciocca, S. Bonato, A. Barbasetti, and G. Alabiso. "Correlation between CA 125, CA 19-9 and Severity of Endometriosis Disease." Journal of Minimally Invasive Gynecology 21, no. 6 (November 2014): S35—S36. http://dx.doi.org/10.1016/j.jmig.2014.08.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Baum, R. P., M. Lorenz, C. Hottenrott, M. Albrecht, R. Senekowitsch, J. Happ, A. Hertel, J. Spitz, and G. Hör. "Radioimmunoscintigraphy Using Monoclonal Antibodies to CEA, CA 19-9 and CA 125." International Journal of Biological Markers 3, no. 3 (July 1988): 177–84. http://dx.doi.org/10.1177/172460088800300306.

Full text

Abstract:

131I labelled F (ab’)2 fragments of monoclonal antibodies against CA 19-9 and CEA (“radioimmunococktail” IMACIS 1) were used in a prospective study (n = 60 patients) and in a retrospective study (n = 32 patients) for the detection of colorectal carcinomas (n = 67) and other gastrointestinal CEA/CA 19-9-producing tumors (n = 32). Sensitivity was 82% and specificity 90%. Immunoscintigraphy proved useful and complementary to CT scan and sonography, especially in the diagnosis of pelvic recurrences and intra-abdominal metastases. In addition, monoclonal antibody OC 125 (IMACIS 2) was used for the detection of ovarian carcinomas (n = 10) and other CA 125 producing tumors. Immunoscintigraphy was positive in all patients (n = 18) suggesting that this radioimmunological approach could be of use in the staging, therapeutic control and earlier diagnosis of recurrent epithelial ovarian carcinoma.

APA, Harvard, Vancouver, ISO, and other styles

21

Göhring, U. J., F. Weber, A. Scharl, and A. Bolte. "Vorkommen der tumorassoziierten Antigene CA 50 und CA 19-9 in Endometriumkarzinomen." Archives of Gynecology and Obstetrics 254, no. 1-4 (December 1993): 993–95. http://dx.doi.org/10.1007/bf02266273.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Inaudi, P., L. Pasqui, G. C. Torre, F. M. Severi, G. Centini, W. Gioffré, S. Danero, and N. D’antona. "CA 125 and CA 19-9 in peritoneal, cyst and amniotic fluids." Medical Oncology and Tumor Pharmacotherapy 5, no. 4 (December 1988): 233–38. http://dx.doi.org/10.1007/bf03003189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Barugola, G., L. Frulloni, R. Salvia, and M. Falconi. "Is CA 19-9 a screening marker?" Digestive and Liver Disease 41, no. 5 (May 2009): 325–27. http://dx.doi.org/10.1016/j.dld.2009.02.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Dalal, Kunal K., Vikram Patel, and Adib Chaaya. "S3329 Pitfall of Elevated CA 19-9." American Journal of Gastroenterology 115, no. 1 (October 2020): S1735—S1736. http://dx.doi.org/10.14309/01.ajg.0000715364.23361.0f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Phillips, K. L., J. H. Garbutt, A. D. Roses, and J. E. Lee. "A chromosome 19 CA-dinucleotide repeat polymorphism." Human Molecular Genetics 1, no. 7 (1992): 551. http://dx.doi.org/10.1093/hmg/1.7.551-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kim, Jaihwan. "Assessment of Asymptomatically Increased CA 19-9." Korean Journal of Pancreas and Biliary Tract 22, no. 3 (July 27, 2017): 114–17. http://dx.doi.org/10.15279/kpba.2017.22.3.114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Matamoros, A. "CA 19-9/Radiation Therapy/Pancreatic Cancer." American Journal of Gastroenterology 93, no. 10 (October 1998): 1798a—1799. http://dx.doi.org/10.1111/j.1572-0241.1998.1798a.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Çakırca, Gökhan. "Comparison of CYFRA 21-1, CEA, CA 19-9 and CA 72-4 levels in gastric cancer." Dicle Medical Journal/Dicle Tıp Dergisi 40, no. 2 (June 1, 2013): 227–30. http://dx.doi.org/10.5798/diclemedj.0921.2013.02.0259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bennett, Katherine, Mary Vargo, Guido Schnabel, and James E. Faust. "Calcium Application Method Impacts Botrytis Blight Severity on Petunia Flowers." HortScience 55, no. 2 (February 2020): 192–95. http://dx.doi.org/10.21273/hortsci14419-19.

Full text

Abstract:

Two application methods of calcium (Ca), fertigation and spray, were investigated regarding their effects on Botrytis blight on petunia (Petunia ×hybrida) flowers. Plants were grown for 6 weeks with three nutrient solutions consisting of 0, 100, or 200 mg·L−1 Ca and weekly calcium chloride (CaCl2) sprays of 0, 750, or 1500 mg·L−1 Ca for a total of nine treatment combinations. Flowers were harvested, inoculated with Botrytis spores, placed in humidity chambers, and evaluated for Botrytis blight severity. Disease severity decreased by 57% and 70% when flowers were treated with Ca spray applications of 750 and 1500 mg·L−1 Ca, respectively; however, no change in disease severity occurred across the Ca fertigation applications. Ca concentration in the flower petal tissue increased with the Ca spray applications: the flower petal Ca concentration increased from 0.26% to 0.65% of tissue dry mass (DM) as the Ca spray application rate increased from 0 to 1500 mg·L−1. However, no change was observed across the Ca fertigation treatments. Leaf tissue Ca concentration increased from 2.1% to 3.2% DM as the fertigation solution increased from 0 to 200 mg·L−1 Ca, whereas spray application had no significant effects of leaf tissue Ca concentration. The results demonstrate that spray application is a more effective technique than fertigation application to provide higher Ca tissue concentrations in flowers, and that the Ca concentration in flower petal tissue is an important consideration when evaluating tissue susceptibility to Botrytis blight. Because of the high rate of fungicide resistance to Botrytis cinerea found in commercial greenhouses, spray applications of CaCl2 are an important disease management tool for commercial growers.

APA, Harvard, Vancouver, ISO, and other styles

30

Thomakos, Nikolaos, Alexandros Rodolakis, Flora Zagouri, Dimitrios Zacharakis, Maria Sotiropoulou, Nikolaos Akrivos, Dimitrios Haidopoulos, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, and Aris Antsaklis. "Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?" Archives of Gynecology and Obstetrics 287, no. 1 (September 1, 2012): 97–102. http://dx.doi.org/10.1007/s00404-012-2529-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ohta, Toshio, Makoto Endo, Takeshi Nakano, Yasuo Morohoshi, and Kouji Wanikawa. "Ca-induced Ca release in malignant hyperthermia susceptible pig." Japanese Journal of Pharmacology 43 (1987): 217. http://dx.doi.org/10.1016/s0021-5198(19)58455-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pilo, Alessandro, Gian Carlo Zucchelli, Richard Cohen, Charles Albert Bizollon, Gino Cappelli, Alberto Cianetti, Massimo Gion, Adriano Piffanelli, and Emilio Bombardieri. "Comparison of Immunoassays for Tumor Markers CA 19-9, CA 15-3 and CA 125: Data from an International Quality Assessment Scheme." Tumori Journal 81, no. 2 (March 1995): 117–24. http://dx.doi.org/10.1177/030089169508100209.

Full text

Abstract:

Data collected in the 1993 and 1994 cycles of an international external quality assessment (EQA) program and in a national multicenter collaborative study were cumulatively analyzed to evaluate the standardization of the methods currently in use for the assay of mucinous tumor markers CA 19-9, CA 15-3 and CA 125. On average the between-laboratory variability was 15.2 and 16.0 CV% for CA 15-3 and CA 125 respectively; the between-laboratory variability found for CA 19-9 was markedly worse (mean 28.3 CV%). The variability component attributable to systematic differences between different methods/kits was relatively small for CA 15-3 and CA 125 (18% and 24% of the total variability) but markedly larger for CA 19-9 (48% of the total variability). The agreement of CA 19-9 results worsened in the last few years when new nonisotopic techniques became available. The precision of the methods/kits most used in the survey ranged from 9.9 to 13.3 CV% for CA 125 and from 11.6 to 13.9 CV% for CA 15-3. For these two tumor markers the precision of the traditional IRMAs does not appear different from that of the new fully automated nonisotopic techniques. The precision of CA 19-9 methods was on average worse (from 11.7 to 19.6 CV%) although two automated systems exhibited a precision better than that of IRMAs. In conclusion, the results of this study indicate that CA 15-3 and CA 125 are satisfactorily assayed whereas CA 19-9 assay appears affected by larger differences between methods and by poorer precision of laboratories and kits.

APA, Harvard, Vancouver, ISO, and other styles

33

Wobbes, T., C. M. G. Thomas, M. F. G. Segers, and F. M. Nagengast. "Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma." Cancer 69, no. 8 (April 15, 1992): 2036–41. http://dx.doi.org/10.1002/1097-0142(19920415)69:8<2036::aid-cncr2820690805>3.0.co;2-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Osswald, B. R., F. E. Klee, and S. Wysocki. "The Reliability of Highly Elevated CA 19-9 Levels." Disease Markers 11, no. 5-6 (1993): 275–78. http://dx.doi.org/10.1155/1993/234238.

Full text

Abstract:

CA 19-9 is used as a tumour marker of the upper gastrointestinal tract. However, extremely elevated CA 19-9 levels are found also in patients with benign diseases. Cholestasis was present in 97.1 % of patients with high elevated CA 19-9, independent of their primary disease. 50% of patients with non-malignant diseases and increased CA 19-9 levels showed liver cirrhosis, cholecystitis, pancreatitis and/or hepatitis. In 8.8% no explanation was found for the extremely high CA 19-9 level. The results provide evidence of different factors influencing the CA 19-9 level.

APA, Harvard, Vancouver, ISO, and other styles

35

Podczaski, Edward, Paul F. Kaminski, and Richard Zaino. "CA 125 and CA 19-9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium." Cancer 71, no. 8 (April 15, 1993): 2551–56. http://dx.doi.org/10.1002/1097-0142(19930415)71:8<2551::aid-cncr2820710819>3.0.co;2-w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

AYDIN, Suphi, Aydın BALCI, and Muhammed EMİN. "Evaluating Lung Cancer with Tumor Markers: CEA, CA 19-9 and CA 125." Journal of Contemporary Medicine 11, no. 3 (May 24, 2021): 282–87. http://dx.doi.org/10.16899/jcm.840949.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Iino, Masamitsu, and Makoto Endo. "The pharmacological properties of the Ca-induced Ca release mechanism and its role in Ca mobilization." Japanese Journal of Pharmacology 40 (1986): 11–12. http://dx.doi.org/10.1016/s0021-5198(19)58893-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Berger, Adam C., Miguel Garcia, John P. Hoffman, William F. Regine, Ross A. Abrams, Howard Safran, Andre Konski, Alan B. Benson, John MacDonald, and Christopher G. Willett. "Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704." Journal of Clinical Oncology 26, no. 36 (December 20, 2008): 5918–22. http://dx.doi.org/10.1200/jco.2008.18.6288.

Full text

Abstract:

Purpose CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma. A secondary end point of Radiation Therapy Oncology Group trial 9704 was prospective evaluation of the ability of postresectional CA 19-9 to predict survival. Methods CA 19-9 expression was analyzed as a dichotomized variable (< 180 v ≥ 180) or (≤ 90 v > 90). Cox proportional hazards models were utilized to identify the impact of CA 19-9 expression on overall survival (OS). Actuarial estimates for OS were calculated using Kaplan-Meier methods. Results Three hundred eighty-five patients patients had assessable CA 19-9 levels. The majority had a CA 19-9 level lower than 180 or ≤ 90 (n = 220 and 200, respectively), while 34% were Lewis Antigen negative and 33 (9%) and 53 (14%) patients had levels higher than 180 and higher than 90. When CA 19-9 was analyzed as a dichotomized variable, there was a significant survival difference favoring patients with CA 19-9 lower than 180 (hazard ratio [HR], 3.53; P < .0001). This corresponds to a 72% reduction in the risk of death for patients with a CA 19-9 lower than 180. This was also true for patients with CA 19-9 ≤ 90 (HR, 3.4; P < .0001). Multivariate analyses confirmed that CA 19-9, when analyzed as both a continuous and a dichotomized variable, is a highly significant predictor of OS in patients with resected pancreatic cancer. Conclusion To our knowledge, this is the first phase III trial to perform prospective analysis of CA 19-9 levels in patients treated with adjuvant chemoradiotherapy. It definitively confirms the prognostic importance of postresectional CA 19-9 levels after surgery with curative intent in patients with pancreatic cancer.

APA, Harvard, Vancouver, ISO, and other styles

39

Mizdrak, Maja, Tina Tičinović Kurir, Ivan Mizdrak, Ivan Jerković, and Ante Mayer. "Characteristics of COVID-19 Infection among Nursing Home Residents." Collegium antropologicum 44, no. 4 (2020): 219–27. http://dx.doi.org/10.5671/ca.44.4.4.

Full text

Abstract:

Given high risk of infection-related mortality due to impaired immunity, elderly patients are at increased risk with COVID-19. In its diagnostic procedure clinical laboratory medicine has a pivotal role. The aim of this study was to investigate clinical and laboratory specificities in Croatian population of nursing home residents affected by coronavirus. One hundred and six residents of nursing homes that were hospitalized due to COVID-19 infection, were included in this retrospective study. Clinical and laboratory findings at three time points were extracted from medical records. There were 86 females and 20 males, with median of age 84 (min-max: 47–97) years. Patients were divided into three groups: Survivors (S), patients who are still alive (N=65), In-Hospital Non-Survivors (IHNS), patients who died from coronavirus during hospitalization (N=31) and Out-of-Hospital Non-Survivors (OHNS), patients who recovered from infection but died during the period of three months of the follow-up (N=10). We have established differences between these three groups in laboratory findings (p<0.05). At the admission, survivors had lower values of lactate dehydrogenase, aspartate transaminase, sedimentation ratio, ferritin and C-reactive protein, OHNS were in the middle, and IHNS had the highest values. Leukocytes and absolute lymphocyte count were greater in OHNS group, and same between survivors and IHNS. After 7 days, we noticed increase in leukocyte and neutrophils count among IHNS. Assessing of complete blood count, differential blood count, reactants of acute infection and combination of their ratios might predict worse outcome in nursing home residents due to coronavirus infection.

APA, Harvard, Vancouver, ISO, and other styles

40

Kyung, Min Sun, Joong Sub Choi, Seung Hwa Hong, and Hak Soon Kim. "Elevated CA 19-9 Levels in Mature Cystic Teratoma of the Ovary." International Journal of Biological Markers 24, no. 1 (January 2009): 52–56. http://dx.doi.org/10.1177/172460080902400108.

Full text

Abstract:

The purpose of this study was to evaluate the clinical value of serum tumor markers in patients with ovarian mature cystic teratoma (MCT). We retrospectively evaluated 163 women who underwent surgery for MCT of the ovary between March 2003 and August 2007 and who provided preoperative blood samples for the measurement of CA 19-9 and CA 125. The rates of elevated serum CA 19-9 and CA 125 levels were 31.9% (52/163) and 13.5% (22/163), respectively. The rate of ovarian torsion was 12.9% (21/163). There were significant differences between the elevated CA 19-9 group and the normal CA 19-9 group in the diameters of the tumors and the rates of ovarian torsion. Elevated serum CA 19-9 levels correlated with larger tumor diameters and higher torsion rates. CA 19-9 may be a useful tool for the diagnosis of ovarian MCT. Elevated CA 19-9 levels appear to correlate with larger tumor diameters and higher rates of ovarian torsion.

APA, Harvard, Vancouver, ISO, and other styles

41

Berger, A. C., K. Winter, J. Hoffman, W. Regine, R. Abrams, H. Safran, A. Konski, A. Benson, J. MacDonald, and C. Willet. "Post-resection CA 19–9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 4522. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4522.

Full text

Abstract:

4522 Background: CA 19–9 is an important tumor marker in pancreatic adenocarcinoma. Several single institutional studies have demonstrated post-resection CA 19–9 to be an important prognostic factor. A secondary endpoint of RTOG 9704, a phase III adjuvant chemoradiation trial for pancreatic cancer, was to prospectively evaluate the ability of post-resectional CA 19–9 to predict survival. Methods: A total of 538 patients were accrued to this trial, of which 385 had evaluable CA 19–9 levels. These were analyzed using ELISA GI-MA kits provided by Diagnostic Products Corporation, a Siemens Company. CA 19–9 expression was analyzed as a dichotomized variable (<180 vs. =180). Cox proportional hazards models were utilized to characterize the contribution of CA 19–9 expression on OS. The following additional variables were included in the multivariate analysis: treatment, nodal involvement, tumor diameter (< or > 3cm), and margin status. Actuarial estimates for OS were calculated using Kaplan-Meier methods. Results: Most patients had CA 19–9 < 180 (n=220, 57%), while 34% were Lewis Antigen negative (unable to express CA 19–9) and 33 (9%) patients had levels >180. Survival was statistically significantly improved among patients with CA 19–9 <180 compared with those whose CA 19–9 =180 (HR=3.58(95% CI=2.40–5.34), p<0.0001) ( table ). This corresponds to a 72% reduction in the risk of death. This improvement was observed among patients with pancreas head and non-head tumors when analyzed separately. The multivariate analysis confirms that CA 19–9 is a highly significant predictor of OS in patients with resected pancreatic cancer. Conclusions: This prospective analysis of CA 19–9 in 385 patients treated with adjuvant chemoradiation definitively confirms the importance of post-resectional CA 19–9 in pancreatic cancer patients who have undergone resection. Patients with post-resection CA 19–9 >180 should be considered for additional therapy. [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

42

Grunnet, Mie, Lene Baeksgaard, Inga Laursen, Ulrik Niels Lassen, and Morten Sorensen. "Using the decline in CA19-9 after the start of chemotherapy to predict survival in patients with inoperable bile duct cancer." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 287. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.287.

Full text

Abstract:

287 Background: CA 19-9 has been approved by the FDA as a tumour marker in pancreatic cancer. The prognostic value of CA19-9 in cholangiocarcinoma is unclear.The aim of the study was to determine if an early CA 19-9 response after the first cycle of chemotherapy is predictive of survival in patients with inoperable bile duct cancer. Methods: CA 19-9 response was defined as a 20% decline in CA 19-9 compared to baseline after four weeks of chemotherapy, in patients with a baseline CA 19-9 level above 1.5 times the upper limit of normal (ULN). Patients were identified retrospectively database at a single institution. Chemotherapy used was gemcitabine day 1 and 15 (1g/m2), oxaliplatin day 1 and 15 (60 mg/m2) and capecitabine (1g/m2 BID) days 1 to 7 and days 15-21 for six cycles. Patients with a baseline CA 19-9 above 1.5 the ULN and at least one CA 19-9 value measured four weeks after the start of chemotherapy were included in the study. Survival in CA 19-9 responders was compared to non-responders by use of the log rank test. A Cox regression analysis was performed using performance status, gender, disease extent and location, need for endoluminal stenting, baseline CA 19-9, and CA 19-9 response as co-variables. Results: 212 patients were registered from Feb 2004 until Nov 2010. Among these, 170 were treated with chemotherapy for cholangiocarcinoma and 131 had a baseline CA 19-9 value and at least one follow-up CA 19-9. Patients with baseline CA 19-9 less than 1.5 times the ULN (n=45) or inconclusive measurements (n=7) were excluded leaving 79 patients in the study. Fifty per cent of patients had a CA 19-9 response to chemotherapy. The median survival in the CA 19-9 response group was 11.7 months (95%CI: 7.5 – 16.0) vs. 8.2 months (95% CI: 6.4 – 9.8) in the non-response group. CA 19-9 response (HR: 0.535 (95%CI; 0.331-0.866), p=0.01) and disease extent (metastasis vs. no metastasis) (HR: 0.604 (95%CI; 0.369-0.99) p=0.046) were independent predictors of survival in a Cox model. Conclusions: CA19-9 response is useful as predictor of survival in patients with inoperable cholangiocarcinoma undergoing chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

43

Rybakov, Ye, Mikhail Tarasov, S. Chernyshov, Marina Sukhina, V. Charikov, Sabina Kozyreva, and V. Kashnikov. "IS A STUDY OF THE LEVEL OF CARBOHYDRATE ANTIGEN (CA 19-9) EFFECTIVE IN PATIENTS WITH COLORECTAL CANCER?" Problems in oncology 66, no. 5 (May 1, 2020): 528–34. http://dx.doi.org/10.37469/0507-3758-2020-66-5-528-534.

Full text

Abstract:

Objective. Саrbohydrаte antigen 19-9 (CA 19-9) is the frequently used tumor marker in the clinical setting of colorectal cancer (CRC). This study was designed to investigate the correlation between preoperative serum levels of CA 19-9 (pre-CA 19-9) and the clinicopathologic factors of patients with CRC. Patients and methods. A study was performed on 482 patients with histologically diagnosed colorectal adenocarcinoma between January 2016 and December 2017, based on retrospective collected data. The clinical data such as age, sex, size of tumor, differentiation (G), depth of tumor (T), lymph node metastasis (N), distant metastasis (M), lymphatic invasion, venous invasion, perineural invasion, stage, and preoperative serum levels of CEA (pre-CEA) and pre-CA 19-9 were obtained. These patients were classified into two groups according to pre-CA 19-9 (CA 19-9 high: H37 U/mL; CA 19-9 normal: H37 U/mL). Results. Eighty five patients among 483 patients (17.6%) with CRC showed a high pre-CA 19-9. The elevationof pre-CA 19-9 was significantly associated with size of tumor > 4.5 cm (р=0.0001), higt CEA > 5ng/ml (р<0.0001), wrong differenciation of tumor (р=0.0003), depth of tumor (р<0.0001), lymph node metastasis (р<0.0001), distant metastasis (р<0.0001), lymphatic invasion (р=0.0013), vascular invasion (р<0.0001), perineural invasion (р<0.0001), stage (р<0.0001). On multivariate analysis, high pre-CA 19-9 was shown to be independently associated with depth of tumor (р=0.05), lymph node metastasis (р=0.0006). Spearman>s correlation coefficient r between REA and CA 19-9 was 0.21 (95% CI 0.13 - 0.30; p<0.0001). Conclusion. High pre-CA 19-9 in advanced colorectal cancer might provide important information to predict the depth of tumor, lymph node metastasis.

APA, Harvard, Vancouver, ISO, and other styles

44

Malaguarnera, Giulia, Saverio Latteri, Roberto Madeddu, Vito Emanuele Catania, Gaetano Bertino, Rosario Emanuele Perrotta, Francesco Dinotta, and Michele Malaguarnera. "High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer." Biomedicines 8, no. 8 (August 3, 2020): 265. http://dx.doi.org/10.3390/biomedicines8080265.

Full text

Abstract:

Background: Non-melanoma skin cancers (NMSC), despite having a favourable prognosis, present an increased risk of occult malignancies. The aim of this study was the evaluation of the usefulness of the mucinous marker carbohydrate 19-9 antigen (CA 19-9) in the diagnosis of occult cancers. (1) Patients and Methods: This is a case control study in which 480 patients with NMSC and 480 matched control subjects with dermatitis were enrolled; 208 patients with NMSC showed upper-normal CA 19-9 values, and 272 showed under-normal CA 19-9 values. (2) Results: The 208 patients positive for CA 19-9 included 87 with basal cell carcinoma (BCC) and 121 with squamous cell carcinoma (SCC). The 272 patients negative for CA 19-9 included 107 with BCC and 165 with SCC. For the SCC patients, CA 19-9 serum levels were significant in 121 of the patients (positive), 66 of which were affected by cancer; CA 19-9 was within the normal range in 165 patients, of which 30 were diagnosed with cancer. In the SCC patients, the CA 19-9 sensitivity was 68%, the specificity was 70%, the positive predictive value (PPV) was 54% (95%) and the negative predictive value (NPV) was 81%. In the BCC patients, the CA 19-9 sensitivity was 70%, the specificity was 66%, the PPV was 48% and the NPV was 83%. In the dermatitis patients (controls), we observed 121 patients that were CA 19-9 positive, with 15 malignancies, and 359 CA 19-9-negative patients, with three malignancies. (3) Conclusions: To confirm the association between CA 19-9 and an elevated risk of malignancies in NMSC, prospective cohort studies should be performed.

APA, Harvard, Vancouver, ISO, and other styles

45

Novis, B. H., E. Gluck, P. Thomas, G. D. Steele, V. R. Zurawski, R. Stewart, P. T. Lavin, and N. Zamcheck. "Serial levels of CA 19-9 and CEA in colonic cancer." Journal of Clinical Oncology 4, no. 6 (June 1986): 987–93. http://dx.doi.org/10.1200/jco.1986.4.6.987.

Full text

Abstract:

The use of serial carbohydrate antigen (CA) 19-9 assays was assessed by comparison with serial carcino-embryonic antigen (CEA) levels on the plasmas of 53 patients with colorectal carcinoma. The patients had all undergone resection for their primary tumors and in six instances subsequent resections for hepatic metastases. Initial CA 19-9 levels were greater than or equal to 37 U/mL in 22 of the 53 patients (41%) and in 68% of the patients with metastatic disease. Similar trends of serial CA 19-9 and CEA levels were found in 79% of the 53 patients. One patient with initially normal CEA levels had elevated CA 19-9 levels from the start. In ten of the 53 patients (19%), serial CA 19-9 levels remained low despite tumor recurrence or progression, and despite increasing CEA levels above 5 ng/mL. The increasing serial CEA trends predicted recurrence in 88% and increasing CA 19-9 trends in 50% of cases, which was increased to 70% by including trends of CA 19-9 levels below 37 U/mL. Following hepatic lobectomy, both serial CEA and CA 19-9 levels decreased rapidly. Used alone, serial CA 19-9 levels did not appear to be as sensitive as standard CEA in this retrospective study of selected patients.

APA, Harvard, Vancouver, ISO, and other styles

46

TCHANTOURIDZÉ, Lasha. "COVID-19: THE CASE OF GEORGIA." Central Asia and The Caucasus 21, no. 3 (September 25, 2020): 070–78. http://dx.doi.org/10.37178/ca-c.20.3.07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Badak, Bartu, and Mustafa Salış. "Kolesistitli Bir Olguda Yüksek CA 19-9 Seviyesi." OSMANGAZİ JOURNAL OF MEDICINE 40, no. 2 (May 1, 2018): 75–77. http://dx.doi.org/10.20515/otd.340155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Bernon, M., Sandie Rutherford Thomson, and E. Jonas. "The rise and fall of CA 19-9." South African Journal of Surgery 51, no. 4 (November 6, 2013): 114. http://dx.doi.org/10.7196/sajs.1973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wilbur, Terence H. "Northwest hispania ca. 1200 b.c. to 19 b.c." Mankind Quarterly 26, no. 3 (1986): 195–205. http://dx.doi.org/10.46469/mq.1986.26.3.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kleinschmidt, M. C., and T. Müller. "Zystische pulmonale Raumforderung und erhöhtes CA 19-9." Der Pneumologe 8, no. 1 (December 15, 2010): 40–43. http://dx.doi.org/10.1007/s10405-010-0459-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Ca 19'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles